Turkey Grants Patent for GeneQuine’s Lead Products [ 02 Mar 2017 ]

Following Europe and China, the Turkish Patent Office grants the Patent for GeneQuine’s Lead Products.

More


Following Europe, China grants Patent for GeneQuine’s Lead Products [ 25 Jan 2017 ]

Chinese Patent Office grants Patent for GeneQuine’s Lead Products.

More


GeneQuine wins Merck’s 2016 European Emerging Biotech Grant Program [ 15 Dec 2016 ]

The Emerging Biotech Grant Program, sponsored by Merck KGaA, helps upcoming biotech companies with financial and research support.

More


GeneQuine to Present at Cell Therapy Manufacturing & Gene Therapy Congress (November 29 - 30, 2016, Amsterdam) [ 23 Nov 2016 ]

GeneQuine's CEO Kilian Guse will present at the Cell Therapy Manufacturing & Gene Therapy Congress on November 29. Dr. Guse will showcase GeneQuine's novel gene therapy platform and highlight data from the lead osteoarthritis development program.

More


GeneQuine to Present at Labiotech Refresh Conference in Paris, November 24th 2016 [ 17 Nov 2016 ]

Labiotech Refresh is Europe's most refreshing Biotech conference, showcasing the industry’s trends in a dynamic and modern way.

More


BioPharm Insight publishes article on GeneQuine [ 10 Nov 2016 ]

GeneQuine's CEO Kilian Guse was interviewed by BioPharm regarding company's technology platform, pipeline and upcoming financing.

More


GeneQuine to Present at Bio Europe Partnering Conference (November 7-9, 2016, Cologne, Germany) [ 03 Nov 2016 ]

GeneQuine's CEO Kilian Guse will present at the Bio Europe Partnering Conference on Nov 9 at 9:30 AM (conference room A, level 0). Dr. Guse will introduce GeneQuine's novel gene therapy platform and highlight data from the lead osteoarthritis development program.

More


GeneQuine’s CEO Kilian Guse to Discuss Advances in Cell and Gene Therapy in Panel Discussion at the Sachs 16th Annual Biotech in Europe Forum, 27 - 28 September 2016, Basel [ 21 Sep 2016 ]

Kilian Guse will discuss advances in cell and gene therapies with other leaders in the field and present GeneQuine’s development programs.

More


GeneQuine to Attend Phacilitate Cell & Gene Therapy Europe Conference, 21-22 September, Berlin [ 13 Sep 2016 ]

GeneQuine Biotherapeutics, a company focused on the development of a novel gene therapy platform, will attend the Phacilitate Cell & Gene Therapy Europe conference held in Berlin.

More


|transkript publishes article on GeneQuine [ 02 Jun 2016 ]

GeneQuine was featured in |transkript, a leading life science magazine in the German-speaking region.

More


GeneQuine’s CEO Kilian Guse to participate in Gene Therapy Panel Discussion at Labiotech Refresh Conference (May 24, 2016, Berlin) [ 18 May 2016 ]

Kilian Guse will discuss the current state and the future of gene therapy at Labiotech Refresh Conference on a panel with other leaders in the field.

More


GeneQuine’s CEO Dr. Kilian Guse to Present at 12min.MED-Life Science (March 17, 2016, University Medical Center Hamburg-Eppendorf) [ 07 Mar 2016 ]

GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at 12min.MED-Life Science.

More


Meet us at the European Animal Health Investment Forum 2016 (February 10 - 11, 2016, London) [ 27 Jan 2016 ]

GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will attend the European Animal Health Investment Forum held in London.

More


Sponsor Fee Waiver for FY 2016 Granted by FDA [ 18 Jan 2016 ]

FDA grants GeneQuine Biotherapeutics a sponsor fee waiver under the significant barrier to innovation provision of ADUFA (Animal Drug User Fee Act) for FY 2016

More


GeneQuine Biotherapeutics to Present at Arabian Tech Tour 2015 (November 2, 2015 in Jeddah, Saudi Arabia) [ 14 Oct 2015 ]

GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at Arabian Tech Tour 2015 in Jeddah, Saudi Arabia. The Arabian Tech Tour offers a platform for high-tech companies to present their business to an invited delegation of international and local investors as well as regional high profile stakeholders.

More


GeneQuine Biotherapeutics to Present at 2015 KC Animal Health Investment Forum (September 1, 2015, Kansas City) [ 18 Aug 2015 ]

GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at 2015 KC Animal Health Investment Forum. The KC Animal Health Investment Forum provides a unique opportunity for companies in the animal health sector to present their vision and business plan to potential investors and development Partners.

More


GeneQuine featured on LaBiotech Tour [ 29 Jun 2015 ]

Within their North German Tour LaBiotech has visited GeneQuine in Hamburg.

More


Animal Pharm publishes article on GeneQuine [ 23 Jun 2015 ]

GeneQuine was featured in Animal Pharm, a leading news website for the animal health sector.

More


GeneQuine’s CEO Interviewed at VetHealth Global 2015 Conference [ 19 Jun 2015 ]

Dr. Kilian Guse was interviewed by Canadian TV on June 8th about the VetHealth Global 2015 Conference and its importance in the Animal Health Industry.

More


GeneQuine Biotherapeutics to Present at VetHealth Global 2015 Conference (June 8-10, 2015, Prince Edward Island, Canada) [ 04 Jun 2015 ]

GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at VetHealth Global 2015, the International Animal Health & Nutrition Business Conference

More


GeneQuine Biotherapeutics Granted Sponsor Fee Waiver by FDA [ 28 May 2015 ]

FDA grants GeneQuine Biotherapeutics a sponsor fee waiver under the significant barrier to innovation provision of ADUFA (Animal Drug User Fee Act) for FY 2015.

More


GeneQuine Biotherapeutics to Present at BioTrinity Conference (May 11-13, 2015, London) [ 04 May 2015 ]

GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at BioTrinity 2015, Europe’s leading Biopartnering and Investment Conference, on May 13, 2015 in London.

More


Michele Sirghita Starts at GeneQuine as Communications Officer [ 01 Mar 2015 ]

Michele Sirghita, BA, has several years of working experience in the field of project management and corporate communications at international consulting and real estate companies.

More


Patent for GeneQuine’s Lead Products Granted by European Patent Office [ 26 Feb 2015 ]

A patent for GeneQuine’s lead products was granted by the European Patent Office, which represents a major milestone in securing intellectual protection in the target markets.

More


Biocentury Publishes Article on GeneQuine [ 22 Dec 2014 ]

GeneQuine was featured as an Emerging Company in the Biocentury journal, the leading provider of biopharma business news, analysis and opinion.

More


GeneQuine Biotherapeutics to Present at Gene Therapy Conference 2014 (December 3-4, 2014, Brussels) [ 01 Dec 2014 ]

GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at Gene Therapy Conference, Europe’s only industry-focused gene therapy Event, on December 4th.

More


Falling Walls Venture Cup [ 08 Nov 2014 ]

GeneQuine Biotherapeutics became second in the Science Startup of the Year competition at the prestigious Falling Walls conference in Berlin.

More


GQ-201 Proof-of-Concept Results presented at Gene Therapy Conference [ 11 Jun 2014 ]

Data of the proof-of-concept study with GeneQuine’s lead candidate GQ-201 were featured in two presentations in May 2014 at the leading gene therapy congress ‘American Society of Gene and Cell Therapy Annual Meeting’.

More


New Website launched [ 22 Feb 2014 ]

Genequine launches new Website.

More


Dr. André Habel starts at GeneQuine as Head of Manufacturing [ 14 Oct 2013 ]

The seasoned expert in GMP manufacturing of viral agents, Dr. André Habel, is GeneQuine's newest addition to the management team.

More


GQ-201 as minor use or minor species product classified [ 10 Oct 2013 ]

GeneQuine received a positive decision by EMA's Committee for Medicinal Products for Veterinary Use (CVMP) on classification of GeneQuine's lead candidate GQ-201 as product for minor use or minor species (MUMS).

More


GeneQuine classified as SME [ 28 May 2013 ]

The European Medicines Agency (EMA) classified GeneQuine as SME (micro, small and medium-sized enterprise).

More


GeneQuine Biotherapeutics closes Seed Financing [ 12 Nov 2012 ]

The Hamburg, Germany-based biotech startup GeneQuine Biotherapeutics today announced the completion of a seven-figure seed financing round. Investors are the German seed funds High-Tech Gründerfonds, Bonn and Innovationsstarter Fonds Hamburg. Funding will be used to perform proof-of-concept studies with the lead product - a gene therapy drug for the treatment of osteoarthritis in horses.

More


GeneQuine starts operations in Hamburg, Germany [ 01 Oct 2012 ]

GeneQuine Biotherapeutics, a privately-held biotech startup company, has started operations in October 2012 in Hamburg, Germany.

More


GeneQuine is "Best of Biotech" [ 10 May 2012 ]

GeneQuine's business case selected as one of the 3 most innovative business ideas at the international business plan competition "Best of Biotech".

More